Bruker Expands Spatial Biology Portfolio with New High-Fidelity Platforms
Event summary
- Bruker announced new advancements in spatial biology at AGBT 2026, including the PaintScape platform for 3D genome visualization and the CellScape XR for high-plex spatial proteomics.
- PaintScape pre-orders begin with shipments expected this spring, offering 419-plex and 1000+-plex panels for chromosomal organization and cancer pathway studies.
- CellScape XR improves throughput, robustness, and flexibility, with commercial shipments expected this summer.
- Bruker introduced the CosMx Mouse Whole Transcriptome assay and plans for spatial miRNA and TCR assays.
- A new collaboration with the University of Glasgow will create a Spatial Biology Center of Excellence for pancreatic cancer research.
The big picture
Bruker's advancements in spatial biology position the company as a leader in high-fidelity, multiomic research tools. The new platforms and collaborations aim to enhance translational and clinical potential, addressing the growing demand for comprehensive spatial biology solutions across DNA, RNA, and protein. The strategic focus on integrating multiomics and expanding assay capabilities underscores Bruker's commitment to driving meaningful patient impact through innovative scientific instruments.
What we're watching
- Technology Integration
- How Bruker will integrate multiomics across platforms to accelerate scientific insights from discovery through translational research.
- Market Adoption
- The pace at which researchers adopt the new PaintScape and CellScape XR platforms for high-fidelity spatial biology studies.
- Collaborative Impact
- Whether the University of Glasgow collaboration will yield significant advancements in pancreatic cancer research and spatial biomarker discovery.
Related topics